<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166124</url>
  </required_header>
  <id_info>
    <org_study_id>16637</org_study_id>
    <secondary_id>I8B-MC-ITRR</secondary_id>
    <nct_id>NCT03166124</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single Dose Administration in Elderly and Younger Adults With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare LY900014 with insulin lispro in elderly and younger
      adults with type 1 diabetes mellitus.

      Screening is required within 28 days prior to the start of the study. For each participant,
      the total duration of the clinical trial will be between 3 to 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">November 18, 2017</completion_date>
  <primary_completion_date type="Actual">November 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Plasma Concentration Curve (AUC) of Insulin Lispro for Each Treatment Arm</measure>
    <time_frame>Predose through 10 hours postdose in each period</time_frame>
    <description>Pharmacokinetics: Area Under the Plasma Concentration Curve (AUC) of Insulin Lispro for Each Treatment Arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm</measure>
    <time_frame>Predose through 10 hours postdose in each period</time_frame>
    <description>Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>LY900014 (elderly group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subcutaneous (SC) dose of LY900014 in the elderly group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (younger adult group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, SC dose of LY900014 in the younger adult group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (younger adult group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin lispro in the younger adult group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (elderly group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin lispro in the elderly group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014 (elderly group)</arm_group_label>
    <arm_group_label>LY900014 (younger adult group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Lispro (younger adult group)</arm_group_label>
    <arm_group_label>Insulin Lispro (elderly group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female participants with Type 1 Diabetes Mellitus (T1DM)

          -  Have a body mass index (BMI) of 18.5 to 30.0 kilogram per meter square (kg/mÂ²)

          -  Have a glycated hemoglobin (HbA1c) less than (&lt;)9.0 percent (%)

          -  Have had no episodes of severe hypoglycaemia in the last 6 months

        Exclusion Criteria:

          -  Have a history or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine (apart from T1DM), hematological, or neurological
             disorders capable of significantly altering the absorption, metabolism, or elimination
             of drugs; of constituting a risk when taking the investigational product; or of
             interfering with the interpretation of data

          -  Have a history of renal impairment

          -  Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg
             vein thrombosis in first-degree relatives

          -  Have proliferative retinopathy or maculopathy and/or severe neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

